Forest Laboratories and Cypress Bioscience have posted more positive late-stage data on milnacipran for the treatment of fibromyalgia.

The companies announced positive top-line results from a 1,025-patient Phase III study, which confirmed the findings from two previous late-stage trials, which showed that milnacipran demonstrated a “highly statistically significant difference to placebo”. The analysis revealed “concurrent and clinically meaningful improvement” in pain, patient global impression of change, and physical functioning and the firms said that comprehensive analyses of the study data will be completed in the coming weeks.

Forest and Cypress are still waiting to hear what the US Food and Drug Administration makes of milnacipran, a selective serotonin and norepinephrine reuptake inhibitor that is already sold by Pierre Fabre outside the USA as an antidepressant, after the agency failed to meet the scheduled Prescription Drug User Fee Act action date of October 18. The FDA has not requested any additional information but indicated that a clinical data question related to the filing required confirmation.

The latest data boosted Cypress shares by 9.2%, though Forest stock barely moved. Last week the latter firm received a proposal from Canada’s TRC Capital for the purchase of less than 1% of its outstanding shares for about $61 million. The company advised stockholders to not tender their shares in the unsolicited mini-tender offer of $20.35 each, a 4% discount to the closing price of Forest from the day before.